News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kibow Biotech, Inc. Showcases RENADYL(TM) at Biotechnology Industry Organization (BIO) 2012 Conference, Boston, MA



6/18/2012 11:59:33 AM

NEWTOWN SQUARE, Pa., June 18, 2012 /PRNewswire/ -- Kibow Biotech is pleased to announce their active participation in the 2012 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year's global event for biotechnology will take place June 18-21, 2012 at the Boston Convention and Exhibition Venter in Boston, MA (http://convention.bio.org/).

Kibow has been chosen to participate in this event to present its uremic toxin reducing technology and to promote RENADYL, the company's patented probiotics dietary supplement for kidney health. RENADYL has been successfully tested in a multi-site, pilot-scale clinical study designed on a model identical to studies carried out on pharmaceuticals (Advances In Therapy, September 2012). An expanded study for this proprietary formulation is in progress at Thomas Jefferson University, Philadelphia, PA and at The Downstate Medical Center/King's County Hospital (State University of New York), Brooklyn, NY.

RENADYL is available exclusively on Kibow's e-commerce site (http://www.renadyl.com). Benefitting from FDA GRAS (generally recognized as safe) status, RENADYL is presently sold primarily in USA and Canada. In clinical tests, the product has proven its ability to help maintain healthy kidney function for those with renal dysfunction or related conditions. Kibow's business presentation is scheduled on Tuesday - June 19 at 9:00 am - 9:15 am (Bruins Room #105).

Dr. Natarajan Ranganathan - one of the key founders and currently the managing director of Kibow - will be presenting and discussing the accomplishments of the company's R&D program, now in its second decade. Dr. Ranganathan will provide an overview of the company's technology and discuss the uses and applications of RENADYL to help maintain healthy kidney function.

Dr. Ranganathan stated, "We were previously honored to have been chosen to present at BIO-2007 Boston event, what was then our developing technology in one of the 20 selected posters at the 'Innovation Corridor' session. This year, we are excited to have the opportunity to present in Boston again at BIO-2012 as a rapidly developing, revenue-generating, mid-stage biotech company."

Kibow Biotech will also be participating as one of seven companies exhibiting in the Pennsylvania Pavilion (#0217) at this BIO-2012 - Boston event.

About the Bio International Convention

The BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. For registration, conference agenda and exhibitor information, visit 2012 BIO International Convention (http://convention.bio.org/).

About Kibow Biotech

Founded in 1997, Kibow Biotech specializes in research and development of probiotic dietary supplements. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health. The Company's flagship product, Renadyl, is currently marketed in the U.S. and Canada, and will progressively be made available worldwide, according to individual countries' governmental rules and regulatory authorities.

About Uremic Toxin Reduction Technology

Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl (for CKD patients) and Azodyl (veterinary formulation) consist of a combination of three specific probiotic microbial strains. The results of a randomized, double-blind, crossover, pilot scale clinical trial completed in 2010 provided encouraging preliminary evidence that the Company's technology could be effective when the formulation is taken together with the standard therapy according to individual patient conditions.

Forward-looking statements

This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Renadyl, for kidney health in the USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Renadyl may not prove to be safe or show evidence of clinical activity in the current limited human trials or that data from patients enrolled in the study may not be useful or conclusive or sufficient to guide future development of Renadyl. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop dietary supplements using the technologies of the Company, risks associated with completing clinical trials of product candidates, the possibility that clinical testing may reveal to be undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators; and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

For further information, contact:

Natarajan Ranganathan, Ph.D.,
Managing Director (R&D)
1 (610) 353 5130
http://www.kibow.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE Kibow Biotech, Inc.


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES